Format

Send to

Choose Destination
Patient Prefer Adherence. 2018 Oct 29;12:2263-2266. doi: 10.2147/PPA.S149423. eCollection 2018.

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia.

Author information

1
Division of Cardiology, Department of Medicine, Mount Sinai Hospital, New York, NY, USA, cekosmas1@gmail.com.
2
Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA.
3
Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA.

Abstract

Evolocumab is a PCSK9 inhibitor which is administered subcutaneously, and when added to statin therapy it has been shown to cause a significant incremental LDL-C reduction, leading to a reduction of cardiovascular risk. Evolocumab has a favorable side effect profile, and its self-administration at home appears to be safe and effective with the appropriate training and instructions from a health care provider. Current studies are showing encouraging results regarding adherence to evolocumab in real-life settings, and adherence rates to evolocumab appear to be better than those to statins. However, further larger studies are needed for a more definitive assessment of the short- and long-term patient adherence rates to evolocumab. In addition, reductions in the price of evolocumab may also be necessary to improve cost-effectiveness of the drug.

KEYWORDS:

adherence; cardiovascular risk; evolocumab; hypercholesterolemia

Conflict of interest statement

Disclosure Dr Constantine E Kosmas reports personal fees from Amgen, outside the submitted work. Dr Eliscer Guzman reports personal fees from Amgen Inc., outside the submitted work. Dr Kosmas and Dr Guzman are members of the Dyslipidemia Speaker Bureau of Amgen, Inc. The authors report no other conflicts of interest in this work.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center